Reich & Binstock
Free Initial Consultation
Toll Free: 877-643-3099
Local: 713-352-7883
877-643-3099 713-352-7883

March 2015 Archives

Risperdal marketing perhaps a case against FDA proposal

Public reaction has been overwhelmingly against proposed U.S. Food and Drug Administration guidance that would allow pharmaceutical companies to market their drugs with information that would contradict the FDA's approved drug warnings. Frankly, the manner in which Janssen marketed the antipsychotic Risperdal, which resulted in the imposition of criminal and civil penalties, may very well have been a case in support of those opponents.

Protecting the rights of medication error victims

Health care professionals generally work hard and provide quality care; nevertheless they are human, and humans can make mistakes. In the case of medication errors, mistakes can cause serious injury or death. Victims or, worst case, the surviving family members of decedents, need an attorney to protect their rights in these unfortunate situations.

FDA issues new anti-infection duodenoscopes guidance

Reacting to the association between the use of duodenoscopes and some patients' development of drug-resistant infections, the U.S. Food and Drug Administration issued new industry recommendations March 12 aimed at helping manufacturers to develop safer reusable medical devices.

Risperdal gynecomastia can be costly

The number of mass tort Risperdal lawsuits filed at a Philadelphia-based trial court has exceeded 1,200. There is still time for a Risperdal victim to contact one of the Risperdal attorneys at Reich & Binstock for a free consultation and possibly for the filing of a Risperdal lawsuit in order to recover damages.

Labels to be changed on approved prescription testosterone products

Stringent safety measures are being taken in regard to prescription testosterone products that the U.S. Food and Drug Administration approved. The FDA announced March 3 that it had required the makers of approved prescription testosterone products to make two key labeling changes. The first labeling change would clarify the approved uses of the products and the second would alert users to the possible increased risk of heart attack and stroke.

Federal Xarelto lawsuits centralized at Louisiana court

Right before the holidays, a federal panel of judges placed numerous Xarelto lawsuits before one court for coordinated pretrial management. The U.S. Judicial Panel on Multidistrict Litigation centralized before the U.S. District Court for the Eastern District of Louisiana 21 federal Xarelto lawsuits that were filed in 22 judicial districts.

Risperdal litigation proceeds

The holidays are over and as early as this month the Philadelphia-based Mass Tort Center at Pennsylvania's First Judicial District has scheduled meetings of the parties involved in Risperdal litigation. In the meantime, the product liability attorneys at Reich & Binstock represent those whose injuries allegedly stemmed from the use of the antipsychotic.

GranuFlo lawsuits swell into the thousands

As of Dec. 15, 2014, there were 2,289 GranuFlo lawsuits pending before the U.S. District Court for the District of Massachusetts. The GranuFlo attorneys at the law firm of Reich & Binstock represent dialysis patients who claim their injuries, or the injuries of family decedents, were the result of GranuFlo risks to which they were unwittingly exposed.

GM ignition switch cases can still be filed

Lawsuits claiming economic damages against General Motors pertaining to an ignition switch defect in GM vehicles are still being filed across the country. A panel of judges in Washington has been transferring many of those economic actions to what is known as a multidistrict litigation court, or MDL, which, in this instance, is the U.S. District Court for the Southern District of New York.

Nearly 70,000 transvaginal mesh lawsuits centralized

As of Jan. 15, nearly 70,000 transvaginal mesh lawsuits filed against seven different TVM manufacturers were centralized at U.S. District Court for the Southern District of West Virginia for pretrial management. Ten months ago, more than 43,000 such cases had been centralized. These are just the federal cases!

Ex-FDA head's testimony looms over Risperdal lawsuits

Physician and former U.S. Food and Drug Administration Commissioner Dr. David Kessler reportedly might testify in Risperdal lawsuit trials that may be held at a Philadelphia trial court. Kessler had submitted documents to the court consistent with the testimony he would have given in 2012 on behalf of the plaintiffs. But a defendant, pharmaceutical corporation Johnson & Johnson, settled several Risperdal lawsuits before trial back then.

Contact Us

Contact Us For Legal Advice

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy

4265 San Felipe
Suite 1000
Houston, TX 77027

Toll Free: 877-643-3099
Phone: 713-352-7883
Fax: 713-623-8724
Map & Directions